Abivax stock at the bottom of the SBF 120 rankings, RSI fallen to 26
The biotech company specializing in inflammatory diseases is accelerating its decline this Thursday, in a Paris market itself under pressure. The stock is experiencing a difficult week, away from all its moving averages, while short sellers remain significantly present in the capital.
A decline that extends the pressure of recent weeks, well below moving averages
Abivax declines 3.34% to €81 during trading, ranking at the bottom of the SBF 120 while the index retreats 0.83%. The decline extends a negative momentum established over recent weeks: the stock loses 10.45% over seven days and 20.43% over one month, erasing a large portion of annual gains which remain positive at 15.22%. The technical configuration reflects this exhaustion.
The price is notably below the MA20 at €95.96 (gap of 15.59%), below the MA50 at €104.09 and below the MA200 at €102.61, with the latter two showing a gap exceeding 21%. The RSI at 26 signals a marked oversold configuration, in line with persistent selling pressure. The support level that served as a reference at €83.80 has been broken and now constitutes a nearby resistance, while the next identified level is situated in the available data without a precise lower level displayed: upside resistance is found at €109.30, or more than 34% above the current price.
Short sellers still present following first-half results
Five funds cumulatively hold 5.84% of Abivax capital sold short, according to consulted filings. This level remains elevated, even though the trend is declining: the cumulative net short position fell by 1.21 percentage points over thirty days, after reaching 7.05% of capital. A bearish bet of this magnitude signals that institutional investors are hedging or betting against the stock, without it being possible to determine the precise reason.
This context comes in the wake of first-half 2026 results, presented on September 21, which reported an expanded net loss and increased research and development spending, with the company targeting obefazimod filing at the end of 2026 with financial visibility extended through the fourth quarter of 2029. The resistance at €109.30, nearly 35% away from today's price, illustrates the scale of the path ahead to erase the recent decline.
